First insight into the drug resistance pattern of Mycobacterium tuberculosis in Dohuk, Iraq: Using spoligotyping and MIRU-VNTR to characterize multidrug resistant strains

Journal of Infection and Public Health

Volumn 4, Issue 1, 2011, Pages 41-47

  Merza, Muayad A ^a,b   Farnia, Parissa ^a   Salih, Ahmad M ^b   Masjedi, Mohammad Reza ^a   Velayati, Ali Akbar ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF DUHOK   (Iraq)

Author keywords

Drug susceptibility testing; Iraq; Molecular genotyping; Multidrug resistant; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DNA FINGERPRINTING; GENOTYPE; HUMAN; INTERSPERSED REPEAT; IRAQ; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS CONTROL; VARIABLE NUMBER OF TANDEM REPEAT;

ANTITUBERCULAR AGENTS; BACTERIAL TYPING TECHNIQUES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; IRAQ; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINISATELLITE REPEATS; MOLECULAR TYPING; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 79951721119     PISSN: 18760341     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jiph.2010.11.002     Document Type: Article

References (32)

1. World Health Organization WHO report 2009. Global tuberculosis control: epidemiology, strategy, financing. WHO/HTM/TB/2009.411 2009, WHO, Geneva.
2. Antunes M.L., Aleixo-Dias J., Antunes A.F., Pereira M.F., Raymundo E., Rodrigues M.F. Anti-tuberculosis drug resistance in Portugal. Int J Tuberc Lung Dis 2000, 4:223-231.
3. Gupta R., Kim J.Y., Espinal M.A., Caudron J.M., Pecoul B., Farmer P.E., et al. Responding to market failures in tuberculosis control: a model to increase access to drugs and treatment. Science 2001, 293:1049-1051.
4. Masjedi M.R., Farnia P., Sorooch S., Pooramiri M.V., Mansoori S.D., Zarifi A.Z., et al. Extensively drug resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006, 43:840-847.
5. Shah N.S., Wright A., Bai G.H., Barrera L., Boulahbal F., Martín-Casabona N., et al. Worldwide emergence of extensively drug resistant tuberculosis. Emerg Infect Dis 2007, 13:380-387.
6. Centers for Disease Control and Prevention Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs-worldwide, 2000-2004. Morb Mortal Wkly Rep 2006, 55:301-305.
7. World Health Organization/International Union Against Tuberculosis and Lung Disease (WHO/IUATLD) Anti-tuberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance 2002-2007. WHO/HTM/TB/2008.394 2008, WHO/IUATLD, Geneva.
8. Merza M.A., Farnia P., Masjedi M.R., Ridell M. Anti-tuberculosis drug resistance in Duhok, Iraq. Int J Tuberc Lung Dis 2010, 14:1213-1214.
9. Van Embden J.D., Cave M.D., Crawford J.T., Dale J.W., Eisenach K.D., Gicquel B., et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993, 31:406-409.
10. Kamerbeek J., Schouls L., Kolk A., van Agterveld M., van Soolingen D., Kuijper S., et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997, 35:907-914.
11. Supply P., Lesjean S., Savine E., Kremer K., van Soolingen D., Locht C. Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. J Clin Microbiol 2001, 39:3563-3571.
12. Kent P.T., Kubica G.P. Public health mycobacteriology: a guide for level II laboratory 1985, Public Health Services, US Department of Health and Human Services, Atlanta, GA.
13. World Health Organization Laboratory services in tuberculosis control. WHO/TB/98.255 1999, WHO, Geneva.
14. Supply P., Mazars E., Lesjean S., Vincent V., Gicquel B., Locht C. Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol Microbiol 2000, 36:762-771.
15. Filliol I., Driscoll J.R., van Soolingen D., Kreiswirth B.N., Kremer K., Valétudie G., et al. Snapshot of moving and expanding clones of M. tuberculosis and their global distribution assessed by spoligotyping in an international study. J Clin Microbiol 2003, 41:1963-1970.
16. Brudey K., Driscoll J., Rigouts L., Prodinger W., Gori A., Al-Hajoj S., et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 2006, 6:23.
17. Vitol I., Driscoll J., Kreiswirth B., Kurepina N., Bennett K.P. Identifying Mycobacterium tuberculosis complex strain families using spoligotypes. Infect Genet Evol 2006, 6:491-504.
18. Allix-Béguec C., Harmsen D., Weniger T., Supply P., Niemann S. Evaluation and user-strategy of MIRU-VNTRplus, a multifunctional database for on-line analysis of genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2008, 46:2692-2699.
19. Surucuoglu S., Ozkutuk N., Celik P., Gazi H., Dinc G., Kurutepe S., et al. Drug-resistant pulmonary tuberculosis in western Turkey: prevalence, clinical characteristics and treatment outcome. Ann Saudi Med 2005, 25:313-318.
20. Al-Marri M.R. Pattern of mycobacterial resistance to four anti-tuberculosis drugs in pulmonary tuberculosis patients in the state of Qatar after the implementation of DOTS and a limited expatriate screening programme. Int J Tuberc Lung Dis 2001, 5:1116-1121.
21. Shamaei M., Marjani M., Chitsaz E., Kazempour M., Esmaeili M., Farnia P., et al. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran - eight years of surveillance. Int J Infect Dis 2009, 13:236-240.
22. Al-Orainey I.O., Saeed E.S., El-Kassimi F.A., Al-Shareef A. Resistance to antituberculosis drugs in Riyadh, Saudi Arabia. Tubercle 1989, 70:207-210.
23. Al-Tawfiq J.A., Al-Muraikhy A.A., Abed M.S. Susceptibility pattern and epidemiology of Mycobacterium tuberculosis in a Saudi Arabian hospital: a 15-year study from 1989 to 2003. Chest 2005, 128:3229-3232.
24. Vareldzis B.P., Grosset J., de Kantor I., Crofton J., Laszlo A., Felten M., et al. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis 1994, 75:1-7.
25. Zignol M., Hosseini M.S., Wright A., Weezenbeek C.L., Nunn P., Watt C.J., et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006, 194:479-485.
26. Dye C., Williams B.G. Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A 2000, 97:8180-8185.
27. Suárez-García I., Rodríguez-Blanco A., Vidal-Pérez J.L., García-Viejo M.A., Jaras-Hernández M.J., López O., et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis 2009, 28:325-330.
28. Caminero J.A. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005, 25:928-936.
29. Faustini A., Hall A.J., Perucci C.A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006, 61:158-163.
30. Mardassi H., Namouchi A., Haltiti R., Zarrouk M., Mhenni B., Karboul A., et al. Tuberculosis due to resistant Haarlem strain, Tunisia. Emerg Infect Dis 2005, 11:957-961.
31. Merza M.A., Farnia P., Salih A.M., Masjedi M.R., Velayati A.A. The most predominant spoligopatterns of Mycobacterium tuberculosis isolates among Iranian, Afghan-Immigrant, Pakistani and Turkish tuberculosis patients: a comparative analysis. Chemotherapy 2010, 56:248-257.
32. Sola C., Filliol I., Legrand E., Lesjean S., Locht C., Supply P., et al. Genotyping of the Mycobacterium tuberculosis complex using MIRUs: association with VNTR and spoligotyping for molecular epidemiology and evolutionary genetics. Infect Genet Evol 2003, 3:125-133.